ArticleJournal of the American Academy of Dermatology2025

Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: A multicenter retrospective cohort study.

Baraa A Hijaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.